Chargement en cours...
Incidence and risk of hand–foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis
BACKGROUND: Cabozantinib is approved in the treatment of progessive, metastatic medullary thyroid cancer (MTC). It is a small molecule inhibitor, which targets multiple receptors including vascular endothelial growth factor receptor, tyrosine kinase with Ig and epidermal growth factor homology domai...
Enregistré dans:
| Publié dans: | Clin Exp Dermatol |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5066302/ https://ncbi.nlm.nih.gov/pubmed/26009777 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ced.12694 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|